Schering-Plough Corp. received recommendation for approval of Suboxone from the Committee for Medicinal Products for Human Use (CHMP) of the EMEA. Suboxone sublingual tablets are for the substitution treatment of opioid dependence, within a framework of medical, social and psychological treatment. Substitution treatment for opioid dependence is when opiate misuse is replaced with an oral opioid medication, such as buprenorphine or methadone, to deter intravenous misuse. Suboxone is intended ...